Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9UII4

UPID:
HERC5_HUMAN

ALTERNATIVE NAMES:
Cyclin-E-binding protein 1; HECT domain and RCC1-like domain-containing protein 5

ALTERNATIVE UPACC:
Q9UII4; B2RTQ1; Q69G20

BACKGROUND:
The protein E3 ISG15--protein ligase HERC5, recognized by its alternative names Cyclin-E-binding protein 1 and HECT domain and RCC1-like domain-containing protein 5, plays a crucial role in the body's defense against viral infections. It is a key player in the ISGylation machinery, targeting a wide array of proteins for ISG15 conjugation. This includes catalyzing the ISGylation of papillomavirus type 16 L1 protein, leading to a reduction in virus infectivity, and broadly modifying newly synthesized proteins in a cotranslational manner, especially under interferon-stimulated conditions.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of E3 ISG15--protein ligase HERC5 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.